The North America osteoarthritis therapy market was valued at US$ 7.87 billion in 2022 and is expected to reach US$ 13.57 billion by 2030; it is estimated to register a CAGR of 7.1% from 2022 to 2030.
In September 2023, Sorrento Therapeutics, Inc. announced positive Phase 2 top-line clinical trial results for the "Resiniferatoxin (RTX) program". The Phase 2 trial is a multi-center, double-blind, placebo, and active-controlled study assessing the efficacy and safety of several dose groups of RTX to manage pain in patients with moderate-to-severe OAK. Also, Sorrento decided to include an active approved competitor drug, "Zilretta," in the current clinical trial protocol.
Further, new product approvals by the manufacturers aiming for non-pharmacology therapy for OA pain further influence market growth. For instance, in June 2021, CyMedica Orthopedics announced receiving approval for the "Intellihab System," a noninvasive modality for knee osteoarthritis pain by the US Food and Drug Administration (USFDA). The new product launch is a therapeutic and digital-based ecosystem that is designed to treat OA pain with a debilitating osteoarthritis disease. Therefore, new non-pharmacology therapy intended for OA pain focusing on reducing dependency on therapeutics is a key factor for fueling the growth of the osteoarthritis therapy market.
More Effective Treatment Options Fuels North America Osteoarthritis Therapy Market
Currently, there is no cure for OA. A group of clinical research scientists, through clinical trials, reveal that they are developing innovative treatment target options that can stop the progression of OA. For example, in November 2021, LG Chem company announced the initiation of a clinical trial for next-generation new drugs to treat arthritis. Additionally, in October 2021, Pacira BioSciences, Inc. announced the acquisition of Flexion Therapeutics to treat non-opioid pain management "ZILRETTA". The drug approved in 2017 is the first and only approved treatment for OA knee pain utilizing extended-release microsphere technology.In September 2023, Sorrento Therapeutics, Inc. announced positive Phase 2 top-line clinical trial results for the "Resiniferatoxin (RTX) program". The Phase 2 trial is a multi-center, double-blind, placebo, and active-controlled study assessing the efficacy and safety of several dose groups of RTX to manage pain in patients with moderate-to-severe OAK. Also, Sorrento decided to include an active approved competitor drug, "Zilretta," in the current clinical trial protocol.
North America Osteoarthritis Therapy Market Overview
North America osteoarthritis therapy market is segmented as US, Canada, and Mexico. Fast product launches by the US Food and Drug Administration (FDA) for osteoarthritis drugs and government support for accelerating product launches are the most impacting factors for the market growth. According to the statistics revealed in the Centers for Disease Control and Prevention (CDC) report, osteoarthritis (OA) is the most common form of arthritis, affecting 32.5 million US adults. Additionally, the Osteoarthritis (OA) Action Alliance report reveals that the overall economic burden associated with OA in the US is estimated at US$ 136.8 billion annually. Further, the American Roentgen Ray Society ARRS report reveals that the lifetime risk of OA is 50%, and it is estimated that by 2040, ~78 million (26%) US adults will have OA.Further, new product approvals by the manufacturers aiming for non-pharmacology therapy for OA pain further influence market growth. For instance, in June 2021, CyMedica Orthopedics announced receiving approval for the "Intellihab System," a noninvasive modality for knee osteoarthritis pain by the US Food and Drug Administration (USFDA). The new product launch is a therapeutic and digital-based ecosystem that is designed to treat OA pain with a debilitating osteoarthritis disease. Therefore, new non-pharmacology therapy intended for OA pain focusing on reducing dependency on therapeutics is a key factor for fueling the growth of the osteoarthritis therapy market.
North America Osteoarthritis Therapy Market Segmentation
The North America osteoarthritis therapy market is categorized into therapy type, disease indications, end user, and country.- Based on therapy type, the North America osteoarthritis therapy market is segmented into transcutaneous electrical nerve stimulation (TENS), occupational therapy, physical therapy, platelet-rich plasma (PRP) therapy & stromal vascular fraction, prolotherapy, and others. The physical therapy segment held the largest market share in 2022.
- In terms of disease indications, the North America osteoarthritis therapy market is segmented into knee osteoarthritis, spine osteoarthritis, foot and ankle osteoarthritis, shoulder osteoarthritis, hand osteoarthritis, and others. The knee osteoarthritis segment held the largest share of North America osteoarthritis therapy market in 2022.
- Based on end user, the North America osteoarthritis therapy market is categorized into hospitals and clinics, specialty clinics, ambulatory surgical center, homecare, and others. The homecare segment held the largest share of North America osteoarthritis therapy market in 2022.
- By country, the North America osteoarthritis therapy market is segmented into the US, Canada, and Mexico. The US dominated the North America osteoarthritis therapy market share in 2022.
Table of Contents
1. Introduction
2. Executive Summary
3. Research Methodology
4. Osteoarthritis Therapy Market Landscape
5. North America Osteoarthritis Therapy Market - Key Market Dynamics
6. Osteoarthritis Therapy Market - North America Market Analysis
7. North America Osteoarthritis Therapy Market Analysis - by Therapy Type
8. North America Osteoarthritis Therapy Market Analysis - by Disease Indication
9. North America Osteoarthritis Therapy Market Analysis - by End User
10. North America Osteoarthritis Therapy Market - Country Analysis
11. Industry Landscape
12. Company Profiles
13. Appendix
Companies Mentioned
- Vision Quest Industries Inc
- Dr PRP USA LLC
- Zimmer Biomet Holdings Inc
- DePuy Synthes Inc
- Bioventus Inc
- Omron Healthcare Inc
- Exactech Inc
- Medi GmbH & Co KG
